Vitara Biomedical Raises $50 Million and Names Kim Rodriguez as Chief Executive Officer
Summary
PHILADELPHIA(BUSINESS WIRE)Vitara Biomedical, a privately held company developing breakthrough technology intended to transform neonatal care, today announced the closing of a $50M funding round. The companys technology was initially developed at Childrens Hospital of Philadelphia (CHOP), one of the leading centers in the world for clinical and scientific innovation in neonatology. Ms. Rodriguez received her Executive MBA from the University of Southern California Marshall School of Business and bachelors degree in management from Pepperdine University.I am delighted to be working with Kim again to develop an innovative healthcare technology that has the potential to change clinical practice for the treatment of extremely premature infants, said Ian W. Ratcliffe, Executive Managing Director of Sands Capital and Vitara Board Director.It is a great privilege to join the Vitara team and to have the opportunity to work alongside the talented and passionate professionals who are developing technology I believe has the potential to save and improve lives of a vulnerable population in dire need of innovation, said Ms. Rodriguez. Current neonatal care is associated with significant morbidity due to iatrogenic injury and developmental immaturity of extreme premature infants.As one of the most active investors in womens health, GV has had the privilege of supporting companies going after ambitious, complex problems in healthcare with the potential to revolutionize the current standard of care, said GV Executive Venture Partner and Vitara Board Observer Cathy Friedman. Vitara stands out with its innovative approach to neonatal intensive care delivery, built on a decade of foundational research.